Fig. 2

Clinical significance of NF2 and RASA1 deficiency in human GC. A Oncoprint of RASA1, NF2, EIF4G2, CDH1, SMAD4, and TP53 mutations in GC. Each column represents one patient as identified in The Cancer Genome Atlas (TCGA) dataset. B Metastasis stage in GC patients depending on RASA1 mutation status in TCGA dataset, classified as M0 (no metastasis), M1 (metastasis present), and MX (metastasis cannot be assessed). P value, chi-square test. C Decreased RASA1 expression was associated with the advanced N stage in human GC tissue microarray (TMA). P value, chi-square test. D Representative RASA1 immunohistochemical images of human GC TMA tissues according to N stage. E Kaplan–Meier plots for the overall survival of patients with GC according to NF2 mRNA expression in the TCGA dataset. P value, log-rank test. F Decreased NF2 expression was associated with the advanced N stage in human GC TMA tissues. P value, chi-square test. G Representative NF2 immunohistochemical images of human GC TMA tissues according to N stage. H Kaplan–Meier plots for the overall survival of patients with GC according to RASA1 mutation and NF2 mRNA expression in TCGA dataset. P value, log-rank test